Panoramic: Automotive and Mobility 2025
Licensing and Commercial Transactions
Our dedicated team of life sciences and health care licensing and commercial transactions lawyers understand the challenges and opportunities that strategic alliances and other partnering relationships present.
We work extensively with pharmaceutical, bioscience, medical device, academic, and other research entities on licensing, collaboration, and commercial transactions involving products and technologies at all stages of the product life cycle and the company’s development. Our breadth of experience, deep industry knowledge, and understanding of the interplay of economic, governance, regulatory, and intellectual property issues enable us to provide comprehensive advice and anticipate the array of issues that may arise.
In a highly regulated industry such as life sciences, easy access to regulatory lawyers to advise on these arrangements is critical. We draw on the depth of our life sciences practice and work seamlessly with our regulatory experts to provide unparalleled transaction support.
We work with you to structure collaborations and commercial transactions that achieve your business goals.
Our capabilities at a glance
00
+
Judicial review wins
2
Ex-government policy advisors
00
+
Pieces of legislation changed
Hear from our clients and industry leaders
The whole team is super smart. They are all really easy to work with and then know our business inside out. They come to us proactively with issues and are incredibly responsive.
Chambers & Partners, UK Guide, 2025
An intellectually brilliant and commercially astute public law team. One of the very best in the city.
Chambers & Partners UK 2025
Hogan Lovells has a high capability in solving complex issues that involve both legal and technical perspectives.
Chambers & Partners, Germany, 2025
The lawyers are just experts. They are there when you need them and happy to entertain all my questions. They understand the wider context and the politics and sensitivities of it.
Chambers & Partners, UK 2025
Representative experience
A global technology company on its joint venture with a global pharma company to enable the research, development and commercialization of bioelectronic medicines.
AmerisourceBergen Corporation on its $6.47bn acquisition of Alliance Healthcare from Walgreen Boots Alliance and all associated commercial transactional agreements.
Intellia Therapeutics in the launch of a new autologous and allogeneic universal CAR-T cell therapy company in collaboration with Blackstone Life Sciences and Cellex Cell Professionals GmbH, the parent company of GEMoaB.
Daiichi Sankyo on multiple transactions, including its collaboration with AstraZeneca to develop and commercialize Daiichi Sankyo’s DS-1062, a potential treatment for multiple tumor types.
BMS on its in-license from Rockefeller University of monoclonal antibodies for the treatment of COVID-19.
Gilead Sciences, Inc. on multiple transactions, including its collaboration with Dragonfly Therapeutics to develop natural killer cell engagers in oncology and inflammation.
Morphosys Ag in the drafting and negotiating of an agreement regarding the co-development and co-marketing as well as the out-licensing (ex-U.S.) of its blood cancer product.
Novartis on multiple transactions, including its COVID-19 and SIV vaccine arrangements with GSK, Roche and CureVac.
Merck KGaAon its up to €1bn immuno-oncology collaboration with F-Star.
SymBio Pharmaceuticals on various licensing arrangements with counterparties in the U.S. and in Europe.
Navigate change with our latest insights
You may also be interested in...
Press releases
Hogan Lovells advises Istituto Gentili on the exclusive partnership with CStone Pharmaceuticals
25 July 2025
Press releases
Hogan Lovells advises Istituto Gentili on the exclusive partnership with CStone Pharmaceuticals
25 July 2025